JCR Pharmaceuticals Co., Ltd. (JP:4552) has released an update.
JCR Pharmaceuticals Co., Ltd. reported a significant decrease in net sales and profits for the first quarter of FY2024, with net sales dropping 24.6% and profit attributable to owners plummeting by 87.5% compared to the previous year. Despite the downturn, the company maintains its dividend forecast of 20 yen per annum and projects a decrease in financial performance for the full year ending March 2025. No changes in accounting policies have significantly affected the reported financial results.
For further insights into JP:4552 stock, check out TipRanks’ Stock Analysis page.
